Pathogenesis, Targeted Therapeutics, and New Vaccines for Childhood Disease
NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development
About This Grant
This supplement to our renewal application seeks continued support for the Vanderbilt Child Health Research Career Development Award (K12) – a program designed to prepare early-career pediatric physician-scientists to become future leaders in basic and translational research. The K12 program provides 80% protected time for mentored research, structured oversight, and individualized career development for up to three years. The Vanderbilt K12 pathway has produced a strong pipeline of pediatric physician-scientists, with substantial return on investment. Among the 11 scholars in the first funding cycle, 73% (8/11) secured individual NIH K awards, and 63% (5/8) of those K-award recipients transitioned to R01-level funding. Program alumni have secured independent research grants and assumed leadership roles in academia, underscoring the program’s impact. Both current K12 Training Directors are products of a Department of Pediatric physician-scientist training pathway (one a former K12 scholar and one a former pediatrics T32 fellow), underscoring our commitment to developing outstanding Vanderbilt Pediatric physician-scientists from fellows through late careers. A central feature of our program for the last 10 years has been the Vanderbilt K12 Club. This monthly forum brings together current scholars, alums, training directors, and multiple PIs to foster peer mentoring, professional development, and knowledge sharing. The program’s mentorship model is tiered and multidisciplinary. Each scholar is guided by a team of senior investigators and “Next Generation” near-peers, including former K12 recipients and mentors, ensuring both expert guidance and relatable peer support. We intentionally align our approach with Social Cognitive Career Theory, which emphasizes how self-efficacy, outcome expectations, and environment influence career development. This theoretical framework underpins our Individual Development Plan process and mentoring strategies, reinforcing scholars’ confidence and persistence. We also added a new mandatory Precision Medicine Research Rotation (1 day/week for 6 months). VUMC’s BioVU links DNA to de-identified electronic health records datasets (Synthetic Derivative, Research Derivative) for genotype–phenotype discovery and validation. Led by Dr. Jennifer Sucre (former K12 scholar and current K12 training director), scholars will build phenotypes, merge genomic and clinical data, and conduct phenotypic and genotypic analyses with bench validation. Additionally, Vanderbilt’s CTSA (Clinical and Translational Science Award) program has supported our scholars by providing infrastructure for clinical research translation, including a biorepository. Collectively, these resources, mentors, and our track record of success provide evidence that the K12 supplement will continue to support the pathway for physician-scientists committed to improving child health.
Grant Summary
Pathogenesis, Targeted Therapeutics, and New Vaccines for Childhood Disease is a NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development grant providing up to $172K for university, nonprofit, healthcare org. Applications are due 2027-03-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $172K
2027-03-31
- 1Confirm your organization is eligible for Pathogenesis, Targeted Therapeutics, and New Vaccines for Childhood Disease from NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Pathogenesis, Targeted Therapeutics, and New Vaccines for Childhood Disease: Frequently Asked Questions
Who is eligible for the Pathogenesis, Targeted Therapeutics, and New Vaccines for Childhood Disease?
Pathogenesis, Targeted Therapeutics, and New Vaccines for Childhood Disease is offered by NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Pathogenesis, Targeted Therapeutics, and New Vaccines for Childhood Disease provide?
Pathogenesis, Targeted Therapeutics, and New Vaccines for Childhood Disease provides up to $172K per award from NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Pathogenesis, Targeted Therapeutics, and New Vaccines for Childhood Disease deadline?
Applications for Pathogenesis, Targeted Therapeutics, and New Vaccines for Childhood Disease are due 2027-03-31 (open). Because deadlines can change, verify the date with the funder, NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Pathogenesis, Targeted Therapeutics, and New Vaccines for Childhood Disease?
To apply for Pathogenesis, Targeted Therapeutics, and New Vaccines for Childhood Disease, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development.